Annual Long Term Debt
$467.58 M
+$54.02 M+13.06%
December 31, 2023
Summary
- As of February 7, 2025, RVNC annual long term debt is $467.58 million, with the most recent change of +$54.02 million (+13.06%) on December 31, 2023.
- During the last 3 years, RVNC annual long term debt has risen by +$259.91 million (+125.15%).
- RVNC annual long term debt is now at all-time high.
Performance
RVNC Long Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Debt
$456.08 M
-$3.94 M-0.86%
September 30, 2024
Summary
- As of February 7, 2025, RVNC quarterly long term debt is $456.08 million, with the most recent change of -$3.94 million (-0.86%) on September 30, 2024.
- Over the past year, RVNC quarterly long term debt has dropped by -$13.30 million (-2.83%).
- RVNC quarterly long term debt is now -2.83% below its all-time high of $469.38 million, reached on September 30, 2023.
Performance
RVNC Quarterly Long Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Debt Formula
Long-Term Debt = Bonds Payable + Long-Term Loans + Mortgage Payable + Other Long-Term Borrowings − Current Portion of Long-Term Debt
RVNC Long Term Debt Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +13.1% | -2.8% |
| 3 y3 years | +125.2% | +42.2% |
| 5 y5 years | +100.0% | +1603.2% |
RVNC Long Term Debt Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +46.2% | -2.8% | +42.6% |
| 5 y | 5-year | at high | +1707.4% | -2.8% | +1663.0% |
| alltime | all time | at high | -100.0% | -2.8% | -100.0% |
Revance Therapeutics Long Term Debt History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $456.08 M(-0.9%) |
| Jun 2024 | - | $460.03 M(-0.8%) |
| Mar 2024 | - | $463.65 M(-0.8%) |
| Dec 2023 | $467.58 M(+13.1%) | $467.58 M(-0.4%) |
| Sep 2023 | - | $469.38 M(+14.0%) |
| Jun 2023 | - | $411.62 M(-0.2%) |
| Mar 2023 | - | $412.63 M(-0.2%) |
| Dec 2022 | $413.56 M(+29.3%) | $413.56 M(-0.2%) |
| Sep 2022 | - | $414.41 M(-0.1%) |
| Jun 2022 | - | $415.00 M(-11.5%) |
| Mar 2022 | - | $468.79 M(+46.6%) |
| Dec 2021 | $319.77 M(+54.0%) | $319.77 M(-0.3%) |
| Sep 2021 | - | $320.79 M(-0.2%) |
| Jun 2021 | - | $321.28 M(+5.0%) |
| Mar 2021 | - | $305.89 M(+47.3%) |
| Dec 2020 | $207.67 M(+702.8%) | $207.67 M(+3.4%) |
| Sep 2020 | - | $200.83 M(+1.3%) |
| Jun 2020 | - | $198.18 M(+1.0%) |
| Mar 2020 | - | $196.19 M(+658.4%) |
| Dec 2019 | $25.87 M | $25.87 M(-3.4%) |
| Sep 2019 | - | $26.78 M(-3.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2019 | - | $27.66 M(-3.0%) |
| Mar 2019 | - | $28.52 M(>+9900.0%) |
| Dec 2018 | $0.00(-100.0%) | $0.00(0.0%) |
| Sep 2017 | - | $0.00(0.0%) |
| Jun 2017 | - | $0.00(-100.0%) |
| Mar 2017 | - | $983.00 K(-47.5%) |
| Dec 2016 | $1.87 M(-65.0%) | $1.87 M(-34.0%) |
| Sep 2016 | - | $2.84 M(-22.5%) |
| Jun 2016 | - | $3.66 M(-18.4%) |
| Mar 2016 | - | $4.49 M(-16.1%) |
| Dec 2015 | $5.35 M(+794.0%) | $5.35 M(-13.4%) |
| Sep 2015 | - | $6.18 M(-11.4%) |
| Jun 2015 | - | $6.97 M(+1259.3%) |
| Mar 2015 | - | $513.00 K(-14.2%) |
| Dec 2014 | $598.00 K(-77.3%) | $598.00 K(-36.2%) |
| Sep 2014 | - | $938.00 K(+33.4%) |
| Jun 2014 | - | $703.00 K(+75.8%) |
| Mar 2014 | - | $400.00 K(-84.8%) |
| Dec 2013 | $2.63 M(-76.1%) | $2.63 M(-45.2%) |
| Sep 2013 | - | $4.81 M(-56.3%) |
| Dec 2012 | $11.00 M(-82.9%) | $11.00 M |
| Dec 2011 | $64.44 M | - |
FAQ
- What is Revance Therapeutics annual long term debt?
- What is the all time high annual long term debt for Revance Therapeutics?
- What is Revance Therapeutics annual long term debt year-on-year change?
- What is Revance Therapeutics quarterly long term debt?
- What is the all time high quarterly long term debt for Revance Therapeutics?
- What is Revance Therapeutics quarterly long term debt year-on-year change?
What is Revance Therapeutics annual long term debt?
The current annual long term debt of RVNC is $467.58 M
What is the all time high annual long term debt for Revance Therapeutics?
Revance Therapeutics all-time high annual long term debt is $467.58 M
What is Revance Therapeutics annual long term debt year-on-year change?
Over the past year, RVNC annual long term debt has changed by +$54.02 M (+13.06%)
What is Revance Therapeutics quarterly long term debt?
The current quarterly long term debt of RVNC is $456.08 M
What is the all time high quarterly long term debt for Revance Therapeutics?
Revance Therapeutics all-time high quarterly long term debt is $469.38 M
What is Revance Therapeutics quarterly long term debt year-on-year change?
Over the past year, RVNC quarterly long term debt has changed by -$13.30 M (-2.83%)